An article Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a beta-Cyclodextrin-PEG Copolymer Based Delivery Platform WOS:000497260700011 published article about POLYMERIC MICELLES; CANCER THERAPEUTICS; ANTITUMOR-ACTIVITY; NANOCARRIERS; RELEASE; NANOTECHNOLOGY; NANOMEDICINE; CHALLENGES; TRANSPORT; CRLX101 in [Metcalf, Chester A., III; Case, Roy I.; Harlfinger, Stephanie; Teng, Chi-Hse] Novartis Inst BioMed Res Inc, 181 Massachusetts Ave, Cambridge, MA 02139 USA; [Svenson, Sonke; Hwang, Jungyeon; Tripathi, Snehlata; Gangal, Geeti; Kabir, Sujan; Lazarus, Douglas; Cole, Roderic; Sweryda-Krawiec, Beata; Shum, Pochi; Brown, Donna; van der Poll, Derek; Rohde, Ellen; Eliasof, Scott] Cerulean Pharma Inc, 35 Gatehouse Dr, Waltham, MA 02451 USA in 2019.0, Cited 68.0. The Name is 2,2′-Disulfanediyldiethanamine dihydrochloride. Through research, I have a further understanding and discovery of 56-17-7. Name: 2,2′-Disulfanediyldiethanamine dihydrochloride
Novel nanoparticle drug conjugates (NDCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successfully generated and tested in drug discovery studies. The NDCs utilized structurally varied linkers that attached the drug payloads to a beta-cyclodextrin-PEG copolymer to form self-assembled nanoparticles. In vitro release studies revealed a diversity of release rates driven by linker structure activity relationships (SARs). Improved in vivo pharmacokinetics (PK) for the cabazitaxel (CBTX) NDCs with glycinate-containing (1c) and hexanoate-containing linkers (2c) were demonstrated, along with high and sustained tumor levels (>168 h of released drug in tumor tissues). This led to potent efficacy and survival in both taxane- and docetaxel-resistant in vivo anticancer mouse efficacy models. Overall, the CBTX-hexanoate NDC 2c (CRLX522), demonstrated optimal and improved in vivo PK (plasma and tumor) and efficacy profile versus those of the parent drug, and the results support the potential therapeutic use of CRLX522 as a new anticancer agent.
Name: 2,2′-Disulfanediyldiethanamine dihydrochloride. About 2,2′-Disulfanediyldiethanamine dihydrochloride, If you have any questions, you can contact Metcalf, CA; Svenson, S; Hwang, J; Tripathi, S; Gangal, G; Kabir, S; Lazarus, D; Cole, R; Sweryda-Krawiec, B; Shum, P; Brown, D; Case, RI; van der Poll, D; Rohde, E; Harlfinger, S; Teng, CH; Eliasof, S or concate me.
Reference:
Thiazine – an overview | ScienceDirect Topics,
,Thiazine | C4H5NS – PubChem